Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Bioequivalence Assessment of Domperidone Maleate Tablets in Healthy Korean Volunteers

  • Published : 2003.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

The bioequivalence of two tablet formulations of 12.72mg domperidone maleate (Sinil "$Perinal^{\circledR}$" tablets vs. Janssen Korea "Motilium-$M^{\circledR}$" tablets) was assessed in healthy Korean volunteers after oral administration in a randomized crossover study. Blood samples were collected at spccified time intervals, and plasma concentration was measured as the amount of domperidone base using a validated HPLC method. The pharmacokinetic parameters of $AUC_{0{\rightarrow}48},\; C_{max},\;T_{max}$ and $t_{1/2}$ were determined from plasma concentration-time profile of two formulations. Any significant statistical differences were not observed between these two formulations. On the evaluation of bioequivalence according to Korea Food and Drug Administration Guideline, 90％ confidence limits after logmithmic transformation fell within the acceptable range (log 0.8∼log 1.25). Based on these data, it can be concluded that two domperidone maleate tablets showed comparable pharmacokinetic profiles, which means that the Sinil "$Perinal^{\circledR}$" tablet is bioequivalent to the Janssen Korea ""Motilium-M$^{\circledR}$".

Keywords

References

  1. Brogden, R. N., Carmine, A. A., Heel, R. C., Speight, T. M. and Avery, G. S. (1982). Domperidone. Drugs 24, 360-400 https://doi.org/10.2165/00003495-198224050-00002
  2. Champion, M. C. (1988). Dornpcridone. Gen. Pharmacol. 19, 499-505 https://doi.org/10.1016/0306-3623(88)90153-X
  3. Champion, M. C., Hartnett, M. and Yen, M. (1986). Domperidone, a new dopamine antagonist. CMAJ 135, 457-461
  4. EMEA (2001). Guidance on the investigation of bioavailobility and bioequivalence, The European Agency for the Evaluation of Meclicinal Products
  5. FDA (2001). Guidance for Industry. Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation ancl Research (CDER)
  6. Heykants, J., Hendriks, R., Meulderrnans, W., Michiels, M., Scheygrond, H. and Reyntjens, H. (1981b) On the pharmacokinetics of dompericlone in animals and man. IV. The pharmacokinetics pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur. J. Drug Metab. Pharmacokinet, 6, 61-70 https://doi.org/10.1007/BF03189516
  7. Heykants, J., Knacps, A, Meulderrnans, W. and Michiels, M. (1981a). On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of dompericlone in ruts and dogs. Age related absorption and passage through the blood brain barrier in rats. Eur. J. Drug Metab. Pharmacokinet. 6, 27-36. https://doi.org/10.1007/BF03189513
  8. Huang, Y.-C., Colaizzi, J. L., Bierman, R. H., Woestenborghs, R. and Heykants, J. J. P (1986). Pharmacokinetics and dose proportionality of domperidonc in healthy volunteers. J. Clin. Pharmacol. 26, 628-632 https://doi.org/10.1002/j.1552-4604.1986.tb02962.x
  9. KFDA (2001). The guideline for bioequivalence test. Korea Food and Drug Administration Act No. 2001-57
  10. Lacluron, P. M. and Leysen, J. E. (1979). Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem. Pharrnacol, 28, 2161-2165 https://doi.org/10.1016/0006-2952(79)90513-6
  11. Lee, Y. J., Kim, Y. G., Lee, M. G., Chung, S. J., Lee. M. H. and Shim, C. K. (2000). Analysis of bioequivalent study using a log-transformed model, Yakhak Hoeji 44,308-314
  12. MacGregor, E. A. (2001). Anti-emesis. Curr. Med. Res. Opin. 17, s22-s25 https://doi.org/10.1185/0300799039117008
  13. Meulderrnans, W., Hurkrnans, R., Swysen, E., Hendrick, J., Michiels, M., Lauwers, W. and Heykants, J (1981). On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of dompericlone in rats, dogs and man. Eur. J. Drug Metab. Pharmacokinet. 6, 49-60 https://doi.org/10.1007/BF03189515
  14. Mitchelson, F. (1992). Pharmacological agents affecting emesis. Drugs 43, 295-315 https://doi.org/10.2165/00003495-199243030-00002
  15. Michiels, M., Hendriks, R., and Heykants, J. (1981). On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur. J. Drug Metab. Pharmacokinet. 6, 37-48 https://doi.org/10.1007/BF03189514
  16. Parfitt, K. (1999). Martindale. The complete drug reference. pp.1190-1191. Pharmaceutical Press. London. UK.
  17. Shargel, L. and Yu, A. B. C. (1993). BioavaiIabiIity and bioequivalence, In Applied Biophannaceutics and Pharmacokinetics, 3rd ed., pp.193-223, Appleton & Lange, Norwalk, USA
  18. Srnit, M. J., Sutherland, F. C. Hundt, H. K, Swart, K. J., Hundt, A. F. and Els, J. (2002). Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the quanitation of clomperidone in human plasma. J. Chromatogr A 949, 6570
  19. Wu, M.S., Gao, L, Cai, X. H., Wang, G. J. (2002). Determination of domperidonc in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. Acta Pharmacal. Sin. 23, 285-288
  20. Yamamoto, K., Hagino, M., Kotaki, H. and Iga, T. (1998). Quantitativc determination or domperidone in rat plasma by highperformance liquid chromatography with fluorescence detection. J. Chromatogr. B 720,251-255 https://doi.org/10.1016/S0378-4347(98)00339-9
  21. Zavitsanos, A. P., MacDonald, C., Bassoo, E. and Gopaul, D. (1999). Determination of dompcridone in human serum and human breast milk by high-performance liquid chromatography-electrospray mass spectrometry. J. Chrornatogt: B 730, 924